What is it about?
Completely resected gastrointestinal malignancies that have spread to the peritoneum in the way of peritoneal metastasis have a high recurrence rate. We systematically review the current evidence on the efficacy and safety of early postoperative intraperitoneal chemotherapy.
Featured Image
Photo by Sharon McCutcheon on Unsplash
Why is it important?
local or metastatic tumor recurrence after Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy is still a problem. Local recurrences eventually lead to malignant bowel obstruction and eventually death in this patient population. Findings ways to prevent local tumor recurrence in completely resected patients with peritoneal carcinomatosis is very important to improve quality of life and survival. Our systematic review shows conflicting evidence on the efficacy and safety of EPIC.
Perspectives
We hope our review will give a good insight to general surgeons, oncologists and surgical oncologists on the current evidence surrounding EPIC. We also hope our research will encourage other units around the world to publish their own experience with EPIC in order to guide optimal therapy for this population of patients.
Mikael Soucisse
Universite de Montreal
Read the Original
This page is a summary of: Early postoperative intraperitoneal chemotherapy for lower gastrointestinal neoplasms with peritoneal metastasis: a systematic review and critical analysis, Pleura and Peritoneum, October 2019, De Gruyter,
DOI: 10.1515/pp-2019-0007.
You can read the full text:
Contributors
The following have contributed to this page
